Background: Sleep disturbances, in particular insomnia, represent a common problem in children with neurodevelopmental disabilities (NDDs). Currently, there are no approved medications for insomnia in children by the US Food and Drug Administration or European Medicines Agency and therefore they are prescribed off-label. We critically reviewed pediatric literature on drugs as well as nonpharmacological (behavioral) interventions used for sleep disturbances in children with NDDs. Methods: PubMed, Ovid (including PsycINFO, Ovid MEDLINE â , and Embase), and Web of Knowledge databases were searched through February 12, 2017, with no language restrictions. Two authors independently and blindly performed the screening. Results: Good sleep practices and behavioral interventions, supported by moderate-to-low level evidence, are the first recommended treatments for pediatric insomnia but they are often challenging to implement. Antihistamine agents, such as hydroxyzine or diphenhydramine, are the most widely prescribed sedatives in the pediatric practice but evidence supporting their use is still limited. An increasing body of evidence supports melatonin as the safest choice for children with NDDs. Benzodiazepines are not recommended in children and should only be used for transient insomnia, especially if daytime anxiety is present. Only few studies have been carried out in children's and adolescents' zolpidem, zaleplon, and eszopiclone, with contrasting results. Limited evidence supports the use of alpha-agonists such as clonidine to improve sleep onset latency, especially in attention deficit/hyperactivity disorder subjects. Tricyclic antidepressants, used in adults with insomnia, are not recommended in children because of their safety profile. Trazodone and mirtazapine hold promise but require further studies. Conclusions: Here, we provided a tentative guide for the use of drugs for insomnia in children with NDDs. Well-controlled studies employing both objective polysomnography and subjective sleep measures are needed to determine the efficacy, effectiveness, and safety of the currently prescribed pediatric sleep medicines in children with NDDs.
Introduction
Sleep disturbances in children with neurodevelopmental disabilities (NDDs), in particular difficulty in falling asleep, night awakenings, and reduced sleep duration, are among the most common parental complaints to health care professionals, with a reported prevalence up to 86% (Robinson-Shelton & Malow, 2016) . Sleep disturbances impact on cognitive and emotional development, aggravating the functional impairment associated with NDDs ( Van de Wouw, Evenhuis, & Echteld, 2012) . Sleep disturbances also affect the entire family environment, disrupting the siblings and marital relationships and increasing the levels of stress (Goldman, Bichell, Surdyka, & Malow, 2012) .
The causes of sleep problems in children with NDDs are often complex and multifactorial: sleep difficulties may be related to co-occurring medical conditions (e.g. epilepsy or gastroesophageal reflux), poor sleep hygiene, or behavioral insomnia of childhood that can be difficult to identify in children with NDDs, often exacerbated by their reduced communication skills. Providers may have received insufficient training, or not have the time to implement behavioral interventions for sleep. Parent-based education and behavioral interventions are the first line of treatment for insomnia, unless symptom severity needs early pharmacotherapy .
In some patients, problematic sleep is a phenotypic characteristic of a particular disorder or genetic condition and the knowledge of the distinctive features of sleep disorders in patients with NDDs is crucial for their effective treatment (Grigg-Damberger & Ralls, 2013) . In other cases, sleep disorders represent a main comorbidity. For instance, a metaanalysis (Cortese, Faraone, Konofal, & Lecendreux, 2009 ) on sleep parameters found that in children with attention deficit/hyperactivity disorder (ADHD), scores of reported bedtime resistance, sleep onset difficulties, night awakenings, difficulties with morning awakening, sleep breathing problems, and daytime sleepiness were significantly higher than in healthy controls. Moreover, sleep disorders might be aggravated by common issues linked to NDDs (such as sensory and motor deficits, psychopathological disturbances, respiratory disorders, epilepsy, and mental retardation), all contributing to the developmental delay.
Although for some NDDs specific sleep disturbances have been reported, (e.g. sleep apnea in Down or Prader-Willi syndromes), the most commonly described sleep complaints in children with NDDs are mainly represented by difficulty in settling at night (present in up to 51% of the patients) and nocturnal awakenings (up to 67%; Quine, 1991) . Fragmented sleep throughout the day and night contributes to daytime sleepiness and irregular sleep schedule, which may lead to a non-24-hr sleep-wake rhythm with a period longer than 24 hr or to a complete reversal of the night-day cycle (Okawa, 1987) .
Although behavioral interventions should be considered the first-line option to address sleep disturbances in children with ADHD, in a sizable portion of patients they need to be complemented by a pharmacological treatment. Currently, there are no medications licensed by the US Food and Drug Administration (FDA) or by the European Medicines Agency (EMA) to treat insomnia in pediatric patients including those with NDDs, and therefore all available drugs are prescribed off-label.
Here, based on a systematic search in a broad set of databases, we critically discuss available evidence for the treatment of chronic insomnia in children and adolescents with NDDs. Although the review is focused mainly on the pharmacological treatments, we include an initial section on nonpharmacological approaches to highlight their relevance as first-line option in the management of sleep disturbances in children with NDDs.
Methods

Search strategy
To ensure a high level of methodological adequacy, as recommended by the Cochrane group (Higgins & Green, 2011) , and avoid the inevitable bias caused by dependence on investigators agreeing to provide data from unpublished studies, we did not search for unpublished data. We excluded nonpeerreviewed references (e.g. conference proceedings) as we considered the peer-review process as essential to the quality of the publication. We retained all types of study designs. We searched the following electronic databases: PubMed, Ovid (including PsycINFO, Ovid MEDLINE â , and Embase), and Web of Knowledge (Web of Science, Biological abstracts, BIOSIS, and FSTA). The specific search terms and syntax for each database are reported in the Supplemental Material. The search was finalized on February 12, 2017. No language limitations were applied to avoid biases due to language restrictions. The reference lists of pertinent reviews/systematic reviews were screened to reduce the likelihood of missing any relevant publication. Two authors (MA and SC) independently and blindly performed the search and screening of papers against eligibility criteria. Any disagreement between the two authors was resolved by consensus. Figure 1 shows the Preferred Reporting Items for Systematic Reviews and MetaAnalyses flow diagram reporting the screening process.
Treatment of chronic insomnia in neurodevelopmental disabilities
Current practice worldwide
In children and adolescents with NDDs, behavioral techniques may be difficult to implement and may take weeks or months to show benefits. Therefore, sleep-promoting agents should be recommended as an option while continuing behavioral intervention. Furthermore, children who do not respond to behavioral interventions may be candidate for the pharmacological treatment of insomnia (Angriman, Caravale, Novelli, Ferri, & Bruni, 2015; Mindell, Kuhn, Lewin, Meltzer, & Sadeh, 2006; Pelayo & Yuen, 2012) .
Due to the paucity of controlled studies, there are no sleep medications approved by the FDA or the EMA for pediatric insomnia in typically developing children, as well as in those with NDDs.
Drugs could be initially useful for relief of parents and children and in general it is better not to wait a long time to treat insomnia, implementing an immediate brief drug trial rather than acting later on a chronic insomnia that has already lasted for several months or years (Pelayo & Dubik, 2008) . Especially in infants and children, chronic insomnia can lead to maternal depression, family dysfunction, and impaired social functioning, but it can also affect the child physical and mental health. Due to these serious implications for both individuals and society, it is essential to treat insomnia either through education of parents, teachers, and other caregivers but also with an effective drug treatment, when insomnia leads to a disruption of family life, or of the child and parent health.
A recent Australian survey on pharmacological management of insomnia in children reported that the most commonly prescribed medications for poor sleep initiation were melatonin (89.1%), clonidine (48%), and antihistamines (29%). Most pediatricians (82%) reported also using behavioral strategies for sleep disturbances, most commonly anxiety relaxation techniques (75%) for poor sleep initiation and graduated extinction (i.e. "controlled crying", 52%) for disrupted overnight sleep. They prescribed melatonin especially for children with autism (85.2%), developmental delay (76.2%), ADHD (54.5%), behavioral disorders (42.6%), visual impairment (40.6%), and anxiety disorders (25.7%). However, over half of the pediatricians (54.5%) prescribed melatonin for typically developing children as well (Heussler et al., 2013) .
A survey by Owens et al. (Owens, Rosen, Mindell, & Kirchner, 2010) showed that more than one third of 1,273 child psychiatrists in the United States treated insomnia with medication at least half of the times in patients with ADHD, autism spectrum disorder (ASD), and with mental retardation/developmental disabilities (MR/DD). Moreover, they reported to treat 17% of preschoolers and at least one-quarter of school-aged and adolescent patients. Overall, 96% of psychiatrists recommended at least one medication in a typical month, and 88% recommended an overthe-counter (OTC) medication. In general, psychiatrists were more likely to use herbal preparations in children with anxiety or mood disorders than in children with NDDs or ADHD; melatonin was recommended by more than one third of them (39%) although it is unclear whether it was being used primarily at bedtime for its mild hypnotic effects or as a chronobiotic. For sleep disorders (mainly insomnia), physicians recommended nonprescription antihistamines in 69% of cases and a-agonists in 67% of children with MR/DD. Trazodone was the second most frequently prescribed medication for children with MR/DD (66%), while sedating antidepressants were used in 75.5% of MR cases. Atypical antipsychotics were used by more than half of the psychiatrists in children with MR/DD (52%) and benzodiazepines were used in 21.6% of cases of MR/DD. Tricyclic antidepressants were also used for children in these diagnostic groups (25.5%).
Although the above-mentioned data come mainly from the United States, similar results have been replicated also in other countries (Bruni et al., 2004; Heussler et al., 2013) . For example, Efron, Lycett, & Sciberras (2014) described sleep medication use in a group of 257 school-aged Australian children with ADHD and 57 of them (22%) were taking sleep medications (melatonin 14% and clonidine 9%). Sleep medication use was associated with combined-type ADHD and ADHD medication use. The presence of cooccurring internalizing and externalizing comorbidities was also associated with sleep medication use in ad-hoc analyses. A recent US study in ASD showed that medications for sleep were prescribed in 46% of 4-to 10-year-old children with autism and sleep difficulties. The most common medication used for sleep was melatonin, followed by a-agonists, and a variety of other medications taken to improve sleep (anticonvulsants, antidepressants, atypical antipsychotics, and benzodiazepines). Children taking medications for sleep had worse daytime behavior and pediatric quality of life than children not taking sleep medications .
Another recent Canadian research (Bock, RoachFox, Seabrook, Rieder, & Matsui, 2016) found that the most common circumstances and sleep problems for which OTC or prescribed medications were recommended were mood disorders, developmental delay, and ADHD (56%, 40%, and 39%, respectively), and insomnia, bedtime struggles/delayed sleep onset, and circadian rhythm disorders (52%, 48%, and 28%, respectively). A total of 30% OTC or prescribed medications were recommended to otherwise healthy children with sleep problems. Melatonin (73%), OTC antihistamines (41%), antidepressants Full-text articles assessed for eligibility (n = 137)
Full-text articles excluded, with reasons (n =15)
Studies included in qualitative synthesis (n =112)
Studies included in quantitative synthesis
(meta-analysis) not applicable Treatment of insomnia in NDD (37%), and benzodiazepines (29%) were the most commonly recommended prescribed medications, respectively.
Nonpharmacological treatment
Prevention is the best treatment for insomnia of childhood but, unfortunately, most parents are referred when the disorder has become chronic. Although we will focus on drug treatment, we should emphasize that when there is a decision to start a pharmacologic intervention, behavioral interventions should be always associated ; good sleep practices and behavioral interventions are the first recommended treatments for pediatric insomnia in either healthy or NDDs children (Honaker & Meltzer, 2014) . The first line of treatment is the promotion of better sleep habits that need to be modified and adapted to these children. This may be somewhat challenging to implement, and should be associated with other behavioral interventions using a gradual approach (such as gradual withdrawal, gradual extinction, and fading), rather than an abrupt change (e.g. extinction techniques), that may be easier and more acceptable for parents as well as being more appropriate for some children with special needs. The choice of a specific form of behavioral intervention should be guided by the parent preferences (Wiggs & France, 2000) and, like in typically developing children, there is no evidence that one approach is more effective than another (Angriman et al., 2015) .
A systematic review of behavioral treatments for insomnia in youth concluded that low-to-moderate level of evidence supports behavioral interventions in adolescents and in children with NDDs (Meltzer & Mindell, 2014) . This review found only two studies involving behavioral interventions for sleep problems for children with special needs that met the inclusion criteria. One study included children with ASDs (Adkins et al., 2012) , whereas the other focused on children with Down syndrome (Stores & Stores, 2004 ). An older study showed that bedtime fading was effective in advancing bedtime hour in three patients with Rett's syndrome. This treatment promoted more regular sleep patterns by increasing appropriate nighttime sleep duration, reducing inappropriate daytime sleep and reducing problematic nighttime behaviors (e.g. nocturnal awakenings; Piazza, Fisher, & Moser, 1991) . There were no significant effects for any of the four sleep outcome measures (Meltzer & Mindell, 2014) but sleep hygiene education was associated with improvement in daytime behaviors, pediatric quality of life, and sense of competence in parents.
Further studies are needed to identify factors that may predict treatment success and to tailor behavioral interventions for young children based on the child (e.g. temperament, age), parental, and environmental factors and on the underlying disease.
Clearly, the involvement of parents as agents for changing problematic sleep behaviors is fundamental; cognitive-behavioral techniques involving parents have been shown to be effective in improving significantly quality of life and well-being of patients and caregivers (Grigg-Damberger & Ralls, 2013; Jan et al., 2008) . Training group of parents in behavioral approaches to manage sleep problems represents a novel behavioral approach: Stuttard et al. (Stuttard, Beresford, Clarke, Beecham, & Curtis, 2015) reported the findings from a preliminary evaluation of a group-delivered intervention routinely delivered by a Child and Adolescent Mental Health Service Learning Disability team in England: parents (n = 23) of children with intellectual disabilities were recruited and the follow-up was of 6 months. No parent dropped out and statistically significant improvements in night wakings, parent-set goals, and parents' sense of efficacy were observed.
As for the treatment of sleep disturbances in specific syndromes, Allen, Kuhn, DeHaai, & Wallace (2013) evaluated the effectiveness of a behavioral treatment package to reduce chronic sleep problems in five children (2-11 years of age) with Angelman syndrome. The treatment package targeted sleep environment, sleep-wake schedule, and parentchild interactions during sleep times. Changes in disruptive bedtime behaviors and in sleep onset were found to be statistically significant. Table 1 summarizes the key principles of nonpharmacological approaches to insomnia in children with NDDs. A novel nonpharmacological approach relies on bed materials and accessories. Gringras et al. (2014) assessed the effectiveness of a weighted blanket intervention in treating severe sleep problems in children with ASD with a randomized, placebocontrolled crossover design. The use of a weighted blanket was not superior, compared to the control condition, to increase sleep duration or to reduce sleep onset delay and night awakenings. More recently, Frazier et al. (2017) in a preliminary, randomized study investigated the efficacy and tolerability of a novel mattress technology -the Sound-To-Sleep system -in the treatment of sleep problems in 45 children with autism, aged 2.5-12.9 years. Satisfactory compliance to this technology was observed and parent-diary outcomes indicated improvements in falling asleep and reduced daytime challenging behavior. Actigraphy-derived sleep parameters indicated significant improvement of sleep duration and sleep efficiency.
Pharmacological treatment
General considerations on prescribing medications for sleep disturbances in children. Before beginning a drug treatment in children with NDDs, different practical aspects should be taken into account: (a) commonly these children are taking other drugs (such as mainly sedatives or antiepileptics) and the eventual interactions should be considered cautiously; (b) the clinician should enquire about previous sleep medications or homeopathic or OTC preparations to consider possible interactions with other medications; (c) the age of the child and his/her clinical history should be taken into account; (d) a thorough sleep history/sleep diary prior to any intervention being planned should be collected. Treatment goals must be established with the parents and, if possible, with the patient and should be realistic, clearly defined, and measurable. The immediate goal of treatment will usually be to alleviate or improve, rather than to completely eliminate, sleep problems; (e) abrupt discontinuation of a sleep medication should be avoided and the treatment should be carefully monitored as there is a natural inclination of the parents to give the lowest dose (Pelayo & Dubik, 2008) ; (f) the choice of the drug, in view of the lack of scientific evidence, should be guided by an accurate evaluation of the main complaint (i.e. difficulty falling asleep, night awakenings, phase advance or delay, nocturnal hyperactivity, midnight awakening, etc.) and also a correct family history can be useful.
The three greatest unmet clinical needs in the treatment of insomnia are residual daytime sedation, tolerance/addiction potential, and improvement in sleep maintenance. Table 2 reports the most commonly used pharmacologic agents for insomnia in children with NDDs.
The following sections summarize the evidence base for the drugs commonly used in chronic insomnia of children with NDDs.
Melatonin. Melatonin (N-acetyl-5-methoxytryptamine) is a chronobiotic and hypnotic agent involved in the regulation of the sleep-wake cycle. In older children and adults, its production and secretion begin in the evening and peak during the night between 2:00 and 4:00 AM and are inhibited by light (Kennaway, 2000) .
A nationwide study showed that hypnotic drug use in 0-to 17-year-old patients increased during the period 2004-2011, from 8.9 to 12.3/1,000, mainly owing to the doubling of melatonin use that was dispensed in the highest annual amount among all hypnotic drugs (Hartz, Furu, Bratlid, Handal, & Skurtveit, 2012) . Approximately 56% of pediatricians prescribed melatonin for sleep onset insomnia (89.1%), delayed sleep phase (66.3%), and nighttime awakenings (30.7%). More specifically, it was prescribed in children with autism (85.2%), NDDs (76.2%), ADHD (54.5%), behavioral disorders (42.6%), visual impairment (40.6%), anxiety disorders (25.7%), and typically developing (54.5%; Heussler et al., 2013) . Systematic reviews and meta-analyses of placebocontrolled, randomized controlled trials (RCTs) in children with NDDs, especially ASD, have demonstrated that, compared to the control condition, exogenous melatonin significantly improves sleep, either by reducing the time to fall asleep (sleep onset latency) or by increasing total sleep time, or both (Braam et al., 2009; Phillips & Appleton, 2004) .
In particular, a large clinical trial confirmed the efficacy of melatonin in the treatment of sleep impairment in children with NDDs, using different doses, ranging from 0.5 to 12 mg; the main effects of melatonin were reduced sleep latency (from 102 to 55 min in 12 weeks) and increased total sleep time (40 min; Appleton et al., 2012) . Another placebocontrolled study in 146 children (age 3-15 years) with intellectual disability showed similar results . Another randomized, placebo-controlled, double-blind, crossover trial of controlled-release melatonin 5-15 mg 20-30 min before bedtime in 50 children with NDDs and delayed sleep phase syndrome (DSPS) confirmed a significant efficacy in decreasing sleep latency (p < .01), albeit with a nonsignificant improvement of total nighttime sleep by 31 min. .
Unlike traditional hypnotics such as chloral hydrate and the benzodiazepines, melatonin does not affect sleep architecture .
With regard to the efficacy/effectiveness of melatonin for specific NDDs, several studies have shown that melatonin (with doses of 1-10 mg given 30-60 min before bedtime) alone or in combination with cognitive-behavioral therapy is effective in insomnia of children with ASD (Cortesi, Giannotti, Sebastiani, (Andersen, Kaczmarska, McGrew, & Malow, 2008; Braam, Didden, Smits, & Curfs, 2008) . Additionally, in nine girls with Rett syndrome (melatonin 2.5-7.5 mg), actigraphy showed that sleep onset latency was significantly decreased while the number of nighttime awakenings was not affected, and the mean total sleep time increased (McArthur & Budden, 1998) .
As for ADHD, a systematic review of the literature concluded that melatonin given at doses 3-6 mg/ night significantly reduced sleep onset latency and increased total sleep duration, but did not impact on daytime ADHD core symptoms (Cortese et al., 2013) . Melatonin has also been found to be effective in children with ADHD with DSPS and insomnia at a dosage of about 5 mg (Smits et al., 2003; Van der Heijden, Smits, Van Someren, & Gunning, 2005; Van der Heijden, Smits, Van Someren, Ridderinkhof, & Gunning, 2007; Weiss, Wasdell, Bomben, Rea, & Freeman, 2006) . A recent randomized controlled trial (RCT) suggested that melatonin (3-6 mg) may be effective in reducing sleep latency in ADHD children with sleep onset delay caused by methylphenidate (Mohammadi et al., 2012) .
Finally, melatonin has been found to be effective also for sleep problems in children with SmithMagenis syndrome, a rare syndrome characterized by an inverted circadian rhythm of melatonin. An open-label study demonstrated that the most efficacious treatment is a combination of acebutolol, a b1-adrenergic antagonist, given in the morning that decreases daytime plasma melatonin levels during the day and exogenous melatonin at night to replace normal peak endogenous melatonin (De Leersnyder et al., 2001) .
From a practical standpoint, in some patients with NDDs, the loss of efficacy of melatonin treatment after an initial good response is a major problem. This is possibly caused by slow metabolism because of decreased activity of the CYP1A2 enzyme in some individuals (Braam et al., 2013) . This may result in increased daily melatonin levels. Consequently, melatonin levels accumulate and after some time, the circadian melatonin rhythm is lost. This loss of circadian rhythm might explain why exogenous melatonin loses its effectiveness over time (Braam et al., 2010) . As a consequence, there is now a greater understanding that low, rather than high, doses (0.5 mg) can be effective for some children, with diminishing benefit with doses exceeding 6 mg.
A single study reported that melatonin for treatment of chronic sleep onset insomnia in children is effective in a dosage of 0.05 mg/kg given at least 1-2 hr before desired bedtime (Van Geijlswijk, van der Heijden, Egberts, Korzilius, & Smits, 2010) .
Headaches, confusion, dizziness, cough, and rashes have been reported, but these common symptoms are likely to be coincidental or caused by impurities in the unregulated formulations of melatonin. Previous reports of poor seizure control, poor asthma control, and adverse endocrinological problems during puberty have not been confirmed. Both systematic reviews and meta-analyses of RCTs suggest that there are no significant adverse side effects associated with the use of melatonin.
Unanswered clinical questions on the use of melatonin include whether slow-release preparations are superior to immediate-release in increasing total sleep time, and whether a more rational and optimal prescription of melatonin might be achieved by measuring salivary melatonin before its use. Table 3 reports some clinical tips on the use of melatonin, suggested during a recent expert consensus conference .
Antihistamines. Histamine is a wake-promoting neurotransmitter, and its inactivation or suppression in various animal models has led to sedation and disrupted wakefulness patterns (Mignot, Taheri, & Nishino, 2002) .
First-generation antihistamines are lipid soluble and pass through the blood-brain barrier; they bind to H1 receptors in the central nervous system (CNS) and have minimal effects on sleep architecture.
Ethanolamines (such as diphenhydramine) have potent sedative effects as do piperazine derivatives (such as hydroxyzine).
Diphenhydramine is the most commonly used and is a competitive H1-histamine receptor blocker. Peak blood and tissue levels are achieved within 2 hr of ingestion. The recommended dosage for adults is 25-50 mg, whereas in children the effective dose is (Russo, Gururaj, & Allen, 1976) . Hydroxyzine is effective at 0.5-1 mg/kg in children (Sezer & Alehan, 2013) . Other antihistaminines have been used: trimeprazine was used in 22 children with night awakenings showing a moderate improvement (France, Blampied, & Wilkinson, 1999) ; niaprazine (1 mg/kg in a single dose at bedtime) showed a decrease of sleep onset latency and an increase of sleep duration (Ottaviano, Giannotti, & Cortesi, 1991) even if compared with benzodiazepines (Montanari, Schiaulini, Covre, Steffan, & Furlanut, 1992) . Although antihistamines are the most prescribed or obtained OTC agents for pediatric insomnia (Schnoes, Kuhn, Workman, & Ellis, 2006) , randomized controlled data in children are lacking. A nonrandomized trial showed a significant decrease in sleep latency time and number of awakenings (Russo et al., 1976) , while another study in infants showed lack of superiority compared to placebo (Merenstein, DienerWest, Halbower, Krist, & Rubin, 2006) .
The most common adverse reaction to antihistamines at therapeutic doses is impaired consciousness. With overdose, adverse effects are predominately anticholinergic, including fever, mydriasis, blurred vision, dry mouth, constipation, urinary retention, tachycardia, dystonia, and confusion. There are some reports on toxicity of diphenhydramine with catatonic stupor, anxiety, visual hallucinations, and more rarely, respiratory insufficiency and seizures (Dinndorf, McCabe, & Frierdich, 1998) with fatal toxicity in five infants of 6-12 weeks old (Baker et al., 2003) . Hydroxyzine seems to be safer and no fatal cases have been reported (Magera, Betlach, Sweatt, & Derrick, 1981) .
It is important to highlight that tolerance to antihistaminergic agents can develop quickly and some children can experience dramatic and paradoxical overarousal (Gringras, 2008) . Due to the lack of controlled trials and the relatively poor tolerability profile, we deem that antihistamines should not be considered as a first-line option for the treatment of sleep disturbances in children with NDDs.
Clonidine. Clonidine is a central and peripheral aadrenergic agonist that acts on presynaptic neurons and inhibits noradrenergic release and transmission, approved by the FDA for the treatment of hypertension, and, in its extended release form, for ADHD. Due to its sedative effects, clonidine is commonly prescribed as a sleep aid in children, but there are no well-controlled studies available (Nguyen, Tharani, Rahmani, & Shapiro, 2014) .
It is hypothesized that clonidine produces sedation decreasing norepinephrine via negative feedback by agonism of the a2-adrenergic receptors at the level of the locus coeruleus, which would increase rapid eye movements (REM) sleep. Administration of low doses of clonidine (range 0.025-0.05 mg) has little effect on sleep and can either increase or decrease the duration of REM sleep. At medium-to-high doses (0.1-0.3 mg/nocte), clonidine appears to have postsynaptic activity on the a2-adrenergic receptors, which results in decrease of acetylcholine, increasing REM latency, stage 2 sleep, and slow-wave sleep (Delbarre & Schmitt, 1971) .
The most commonly reported side effects of clonidine include drowsiness, transient sedation, headache, dizziness, fatigue, somnolence, insomnia, hypotension, and bradycardia.
In a retrospective chart review, Ingrassia and Turk (2005) found clonidine to be an effective therapeutic intervention for alleviating sleep disturbances in six children with NDDs, aged 6-14 years at a dose of 0.05-0.1 mg at bedtime. No relevant side effects were reported.
In another retrospective review, 19 children with ASD were treated with oral clonidine at 50 lg with a slow titration up to 100 lg, 30 min before bedtime, reporting reduced sleep latency and nocturnal awakenings. The most common reported adverse effects included skin irritation with transdermal administration, and daytime drowsiness with administration of tablets (Ming, Gordon, Kang, & Wagner, 2008) .
Overall, in a comprehensive literature review of noncontrolled studies, Hollway and Aman (2011) showed that clonidine was effective on sleep disturbances in children with comorbid ASD and other NDDs at doses ranging from 0.05 to 0.225 mg/day.
Of note, in children who are taking concomitant CNS-depressing agents and in individuals with hemodynamic instability or cardiac pathology, the use of clonidine should be accurately monitored (Spiller et al., 2005) .
Benzodiazepines: Clonazepam. Benzodiazepines bind to the benzodiazepine subunit of the c-amino butyric acid (GABA) chloride receptor complex, facilitating the action of the inhibitory neurotransmitter GABA. These hypnotics have long been the firstchoice treatment for insomnia in adults, but their use raises concerns about cognitive impairment, rebound insomnia, and the potential risk for dependence.
Only a very limited number of open studies testing the effectiveness and tolerability of benzodiazepines in children have been published. In five children aged 1.5-10 years with Williams syndrome, clonazepam 0.25-0.75 mg at bedtime, determined an immediate improvement in nighttime awakenings and daytime behaviors in four of the five patients that persisted at 3-to 6-month follow-up (Arens et al., 1998 ). An effect on REM sleep behavior disorder in a child with autism has been reported (Thirumalai, Shubin, & Robinson, 2002) .
Concerns on their tolerability profile, along with the limited availability of evidence-based data in the pediatric population, contribute to limit their use in children (Owens, 2011 ). Short-term or as-needed administration is the most frequent suggested treatment. Based on available data, clonazepam may represent a treatment option in children with arousal disorders (parasomnias) or periodic leg movement disorder or restless legs syndrome (RLS), but future trials focused on objective sleep measures and safety issues are needed.
Non-benzodiazepine sedative-hypnotics (Z drugs). Z drugs are non-benzodiazepine receptor agonists that bind preferentially to GABA A receptor complexes containing a 1 subunits; they have minimal effects on sleep architecture with a slight increase slowwave sleep (Zisapel, 2012) .
There are very few studies conducted in children. One trial reported children with ADHD and insomnia aged 6-11 years or 12-17 years receiving treatment with zolpidem at 0.25 mg/kg per day (max 10 mg/ day) versus placebo reported a mean change in latency to persistent sleep at week 4 that did not differ between zolpidem and placebo groups. No next-day residual effects of treatment and no rebound phenomena occurred after treatment discontinuation (Blumer, Findling, Shih, Soubrane, & Reed, 2009) . Eszopiclone failed to show a benefit over placebo in a group of 371 children aged 6-17 years with ADHD and sleep disturbances; dosedependent adverse events were reported in 46-61% of patients (Sangal, Blumer, Lankford, Grinnell, & Huang, 2014) . The most frequent adverse events (>5%) were dizziness and headache and also disinhibition and hallucinations have been reported (Liskow & Pikalov, 2004) .
Antidepressants. Tricyclic and atypical antidepressants (mirtazapine, nefazodone, and trazodone) are used in clinical practice to treat insomnia in adult and pediatric populations. Their effects on sleep are mediated by an action on different neurotransmitters, such as serotonin, histamine, and acetylcholine, involved in sleep regulation.
Tricyclic antidepressants: Tricyclic antidepressants (amitriptyline, trimipramine, and doxepin) determine a reduction of REM and slow-wave sleep and have been used to treat insomnia. Both amitriptyline and trimipramine have been shown to have sedative effects in adults (Holmberg, 1988; Riemann et al., 2002; Ware, Brown, Moorad, Pittard, & Cobert, 1989) .
There are no data supporting the use of amitriptyline or trimipramine in children with NDDs; however, amitriptyline is commonly used in children with NDDs beginning with a very low dose (5 mg) followed by gradual increase, up to 50 mg, until the desired effect is achieved.
Doxepin:
In adults, doxepin (3-6 mg) has been shown to improve sleep maintenance and early morning awakenings; when used in children with pruritus, it led to CNS depression (Zell-Kanter, Toerne, Spiegel, & Negrusz, 2000).
Side effects of tricyclics include anxiety and agitation, anticholinergic effects (e.g. blurred vision, dry mouth, urinary retention, and orthostatic hypotension), cardiotoxicity, and worsening of RLS symptoms.
Mirtazapine: Mirtazapine is an a2-adrenergic, 5-HT receptor agonist with a high degree of sedation at low doses (Younus & Labellarte, 2002) . It has been shown to decrease sleep onset latency, increase sleep duration, and reduce wake after sleep onset (WASO), with relatively little effect on REM sleep (Wichniak, Wierzbicka, & Jernajczyk, 2012) .
There is a single open-label study in autistic children and children with other forms of pervasive developmental disorders, which suggests some efficacy for insomnia; 9 out of 26 subjects (34.6%) were judged to be responders, based on their improvement in a variety of symptoms, including aggression, self-injury, irritability, hyperactivity, anxiety, depression, and insomnia (Posey, Guenin, Kohn, Swiezy, & McDougle, 2001) .
Trazodone: Trazodone is one of the most sedating antidepressants available and the most widely studied of antidepressants in terms of sleep in adults. It was the most commonly prescribed insomnia medication for children with mood and anxiety disorders in a survey of child and adolescent psychiatrists in the United States (Owens et al., 2010) .
Its action is mediated by the 5-HT2A/C antagonism and inhibition of postsynaptic binding of serotonin and blocking of histamine receptors.
Recent empirical evidence suggests that trazodone may interact with the melatonin system. Giannaccini et al. (2016) measured clinical and melatonin parameters before and after 1 month of therapy with trazodone in insomniac mood-depressed patients. Patients with refractory depressed-mood and insomnia improved after treatment and responsive patients excreted more urinary 6-hydroxy-melatonin sulfate than before treatment, reflecting an enhanced nighttime production of the pineal hormone in these subjects and suggesting an interaction between trazodone and melatonin system. Based on these data, the authors supported the role of melatonin as a biological indicator of prohypnotic and antidepressant benefits of trazodone.
Trazodone suppresses REM sleep and increases slow-wave sleep, which may prove to have beneficial effects in memory function of children who are challenged intellectually and who struggle to generalize and maintain adaptive skills of daily living.
Despite being commonly used to manage insomnia in the clinical practice, only very few studies have been conducted in children and adolescents to test the effectiveness and tolerability of trazodone as a sleep medication.
Trazodone has been used for insomnia in 17 children with opsoclonus-myoclonus syndrome (Pranzatelli et al., 2005) . The starting dose of 25 mg was increased to a maximum of 100 or 150 mg depending on age. The effects on sleep were not dose-dependent and low dosages were effective for insomnia. Additionally, anecdotal reports show the efficacy of trazodone mainly in midnight and terminal insomnia.
The most commonly reported side effects are dry mouth, nausea, vomiting, drowsiness, dizziness/ light-headedness, headache, and morning hangover. Less common or rare side effects are hypotension, tachycardia, serotonin syndrome, and priapism (Bossini et al., 2015) . It is not commonly indicated in Rett syndrome for the risk of QT interval prolongation. It should be noted that, as the doses of trazodone for insomnia are lower than those used for depression, the incidence of side effects is generally also lower.
Atypical antipsychotics. Atypical antipsychotics such as risperidone, quetiapine, aripiprazole, and olanzapine are typically used off-label in children with psychiatric or developmental disorders to reduce disruptive behaviors (Capone, Goyal, Grados, Smith, & Kammann, 2008; Masi et al., 2009 ). Risperidone and olanzapine have been prescribed also for sleep disturbances in children, but no studies are available evaluating their safety and effectiveness (Hollway & Aman, 2011; Meltzer, Mindell, Owens, & Byars, 2007; Schnoes et al., 2006) . Tolerability profile of these medications can be highly problematic: excessive weight gain may exacerbate any sleep-disordered breathing present in the child; metabolic effects like hyperglycemia or hyperprolactinemia may be unsafe in certain clinical conditions (i.e. Down syndrome or Prader-Willi syndrome).
Atypical antipsychotics (e.g. risperidone or aripiprazole) should be considered to treat a comorbid condition (i.e. aggressive, self-injurious behaviors in children with ASD) and they might help to relief from insomnia when dosed at bedtime.
A small randomized and placebo-controlled study of quetiapine (25 mg/nocte, a relatively low dose) in adults showed a statistically nonsignificant trend toward improvement in total sleep time and reduced sleep latency (Tassniyom, Paholpak, Tassniyom, & Kiewyoo, 2010) .
There is a single open-label trial involving 11 children with ASD which did demonstrate a significant reduction in sleep disturbance (Golubchik, Sever, & Weizman, 2011) .
Due to the paucity of data and, especially, to the tolerability profile, the use of neuroleptics for insomnia in children, considering their tolerability profile, is generally not recommended.
Gabapentin. Food and Drug Administration approved gabapentin for the treatment of partial seizures in 1993. It was originally designed as a precursor of GABA that easily enters the bloodbrain barrier, and increases brain synaptic GABA. More recently, it has been approved for the treatment of neuropathic pain and RLS in addition to its original purpose as an anticonvulsant medication. However, its precise pharmacological mechanism in humans remains unknown. In addition to its demonstrated efficacy in these indications, patient-reported sleep assessments among a variety of clinical conditions suggest that gabapentin has beneficial effects on sleep. The improvement of sleep might be mediated by the increase in slowwave sleep and the decrease of WASO (Rosenberg et al., 2014) .
In a recent case series, gabapentin was found to be a safe and a well-tolerated treatment for sleep onset and sleep maintenance insomnia in 23 children, 87% of whom had NDDs. Following gabapentin treatment initiated at an average dose of 5 mg/kg (range 3-7.5 mg/kg) 30-45 min before bedtime, with titration to a maximum dose of 15 mg/kg (range 6-15 mg/kg), 78% of children showed improvement in sleep (as reported by parents). Furthermore, this beneficial response was noted at doses of 5-15 mg/kg orally at bedtime, much lower than the recommended dose to treat epileptic seizures (40 mg/kg divided three times daily). Side effects in a few cases included agitated nighttime awakenings and difficulty falling asleep (Robinson & Malow, 2013) .
Ramelteon. Ramelteon is a synthetic melatonin receptor agonist with high affinity for the MT1 and MT2 receptors, and is approved by the FDA for use in adults. Only few case reports have been published in children with NDDs reporting in general limited efficacy on night awakenings (Asano, Ishitobi, Kosaka, Hiratani, & Wada, 2014; Miyamoto et al., 2013; Stigler, Posey, & McDougle, 2006) . Chloral hydrate. Chloral hydrate has been suggested to be effective for nighttime sedation in children as it was initially considered a safe agent in infants and young children at dosages of 25-100 mg/kg/day. However, respiratory depression and hepatotoxicity have been reported after administration of chloral hydrate (Biban, Baraldi, Pettennazzo, Filippone, & Zacchello, 1993) .
Therefore, chloral hydrate should be avoided or at least carefully controlled in children with NDDs at risk for obstructive sleep apnea (Sheldon, 2001 ). Additionally, it may cause gastric distress, nausea, vomiting, drowsiness, dizziness, malaise, and fatigue. Children may experience idiosyncratic reactions characterized by confusion, disorientation, and paranoia. Used chronically, chloral hydrate is habit forming and associated with tolerance (Glaze, 2004) .
Orexin antagonists. Recently, orexin neuropeptides have been identified as regulators of the sleep/ wakefulness transition and shown to aid an initial transitory effect toward wakefulness by activating cholinergic/monoaminergic neural pathways of the ascending arousal system (Chow & Cao, 2016) .
Orexins hold an important role in the wakefulness promoting ascending arousal system by having an excitatory effect on almost every wake-promoting neuronal group of reticular ascending system and represent the critical modulators of the sleep-wake cycle homeostasis.
Orexin receptor antagonists can be classified on the basis of receptor-binding affinities, either as selective orexin receptor antagonists (i.e. selective for OX1 or OX2 receptors) or dual orexin receptor antagonists (i.e. compound with spread binding capacity to OX1 and OX2; Kumar, Chanana, & Choudhary, 2016) . It has been hypothesized that antagonizing both orexin receptors would elicit the most powerful sleep-promoting effects (Morairty et al., 2012) .
Dual orexin receptor antagonists molecules (almorexant and suvorexant) administered to healthy volunteers and patients with insomnia have been shown to effectively reduce the number of awakenings and sleep latency while increasing total sleep time (Kumar et al., 2016) .
The most frequent dose-dependent adverse effects are mild somnolence, headaches, dizziness, and abnormal dreams (Bennett, Bray, & Neville, 2014) .
The major route of metabolism for almorexant and suvorexant is CYP3A. Suvorexant is the most widely studied and concomitant use with CYP3A Inhibitors is not recommended as the effects could be increased about two-to threefolds (e.g. ketoconazole, itraconazole, clarithromycin, nefazodone, ritonavir, saquinavir, nelfinavir, indinavir, boceprevir, telaprevir, ciprofloxacin, diltiazem, erythromycin fluconazole, grapefruit juice, and verapamil). On the other hand, strong CYP3A inducers can substantially decrease almorexant and suvorexant exposure (e.g. rifampin, carbamazepine, and phenytoin; Kishi, Matsunaga, & Iwata, 2015) .
This category of compounds might be promising for children with NDDs as they act on a different neurotransmitter system with less interactions with other drugs commonly used in these children. RCTs are needed to assess both the short-and long-term effects of these medications, as well as their efficacy in comorbid diseases that affect sleep architecture.
Tryptophan/5-hydroxytryptophan (5-HTP). Tryptophan is a precursor of serotonin and melatonin, widely used in the 1980s for the treatment of sleep disorders and headache prophylaxis. It does not have opioid-like effects and does not impact on cognitive performance or inhibit arousal from sleep (Lieberman, Kane, & Reife, 1985) . Several positive effects on sleep have been reported: improvement of sleep latency and decrease of arousals (Hartmann & Spinweber, 1979; Schneider-Helmert & Spinweber, 1986) . 5-HTP is the intermediate metabolite of the essential amino acid L-tryptophan (LT) in the biosynthesis of serotonin. It easily crosses the blood-brain barrier and effectively increases CNS synthesis of serotonin. The effects of 5-HTP on sleep structure are conflicting: increase or decrease of REM and increase of slow-wave sleep (SWS; Meolie et al., 2005) .
The exact mechanism of action of the sedative effects of 5-HTP is not completely clear and it is not sure that it is mediated only by conversion in serotonin. Serotonin (5-HT) should not be considered either wake-promoting or SWS-promoting, the effect of 5-HT on sleep-wake behavior would depend upon the activation of the serotonergic system (systemic administration of low vs. high doses of the precursor 5-HTP), and the time at which the activation occurs (light vs. dark period of the light-dark cycle; Imeri, Mancia, Bianchi, & Opp, 2000) . It has been hypothesized that the 5-hydroxytryptophan-related increase of SWS during the dark period depends upon the synthesis or release of as yet to be identified sleeppromoting factors (Monti, 2011) .
In terms of available evidence, one study with LT at different dosages (250 mg, 1 g, and 3 g) in adults showed a significant improvement in sleep latency, along with a reduction in WASO, with a moderate effect on quality of sleep. None of the published studies reported systematic information regarding adverse effects associated with tryptophan (Hartmann, Lindsley, & Spinweber, 1983; Hudson, Hudson, Hecht, & MacKenzie, 2005; Spinweber, 1986) .
No data are available on the effects of 5-HTP on insomnia symptoms in children with NDDs.
Iron. Iron is a cofactor for tyrosine hydroxylase, the enzyme responsible for catalyzing the conversion of the amino acid L-tyrosine to dopamine.
Iron deficiency anemia in infancy has been reported to be associated with higher motor activity during sleep, shorter night sleep duration, and higher frequency of night waking (Kordas et al., 2008) , and supplemental iron was associated with longer sleep duration (Kordas et al., 2009) .
Because iron deficiency is common in children, measuring the ferritin level is reasonable. Different reports showed a relation between low serum ferritin levels and insomnia associated with sleep hyperkinesia [i.e. RLS or periodic limb movements of sleep (PLMs)] in children with ADHD or ASD (AbouKhadra, Amin, Shaker, & Rabah, 2013; Cortese, Konofal, Dalla Bernardina, Mouren, & Lecendreux, 2009; Dosman et al., 2007) .
A recent review showed an increased incidence of PLMs (42%) compared with controls (8%) in 53 pediatric patients with ASD with low serum ferritin level (below 35 ng/ml); sleep fragmentation and poor sleep efficiency were associated with lower median ferritin level (Youssef, Singh, Huntington, Becker, & Kothare, 2013) .
In 102 children (68 with ASD, 18 typically developing, and 16 with developmental delay), an increase of PLMs has been found (Lane et al., 2015) , but serum ferritin level was not significantly correlated to any sleep parameter.
Iron supplementation (6 mg/kg/day of elemental iron) in 33 children with ASD showed an improvement of restless sleep score but no relation was found with serum ferritin concentrations (Dosman et al., 2007) .
When poor sleep is reported in children with ADHD or NDDs, serum ferritin levels should be monitored and questions on restless sleep should be asked. If ferritin levels are <50 lg/L, 1-2 mg/kg/day of elemental iron (up to 6 mg/kg/day of elemental iron) should be administered (Abou-Khadra et al., 2013; ). Parents should be asked for a personal and family history of hemochromatosis. The few published studies suggest vitamin D supplementation may improve sleep quality; especially in patients with neurologic complaints who also have evidence of abnormal sleep. Most patients have improvement in neurologic symptoms and sleep but only by maintaining a narrow range of 25(OH) vitamin D3 blood levels of 60-80 ng/ml (Gominak & Stumpf, 2012) .
Vitamin D is related to dopamine metabolism. It could be useful to investigate vitamin levels in association with iron parameters in children with NDDs and insomnia associated with motor hyperactivity during sleep.
Conclusions
Insomnia in children with NDDs, along with the other neurobehavioral comorbidities, affects the quality of life of both children and families, is associated with poorer developmental outcome, and contributes to worsen behavioral disturbances.
While behavioral interventions should be the firstline approach, in a sizable portion of cases, a pharmacological approach needs to be considered. Despite the widespread use of pharmacological treatment, the lack of well-designed, controlled studies on the efficacy/ effectiveness, tolerability, dosage, and safety profile of hypnotic medications in children raise the need of further research in this field of sleep medicine.
The lack of research in this area is detrimental for children and their families and well-conducted trials should be performed, based on the physiopathology of the disorders, evaluating also the presence of other comorbid sleep disorders and addressing the correct choice of drugs, not based only on their sedative or anxiolytic effects.
With the support of expert recommendations and empirical evidence, we propose two algorithms for the management of chronic insomnia in children with NDDs. Figure 2 manifestations. Figure 3 shows the management algorithm for chronic insomnia in patients with some specific NDDs. Importantly, given the lack of head-tohead trials and network meta-analyses, it is not possible to provide an evidence-based hierarchy of available medications in terms of efficacy/effectiveness and tolerability, although, given their tolerability profile, we discourage the use antipsychotics and benzodiazepines as first-line treatment for sleep disturbances in children with NDDs. The drugs indicated in the flowchart are represented as a hierarchy of choice based on expert clinical experience and should be considered as a generic indication. The choice, the combinations of the drugs, and the switch between them should be adapted to each single case. Future research will hopefully lead to a development of a drug with proved efficacy and suitable safety profile that will allow a better health and quality of life of children and adolescents with NDDs and their families.
Recommendations for future research
The treatment of insomnia in special populations such as children with NDDs is a field that needs to be better explored because it is extremely important to improve sleep quality and quantity in children with NDDs. Improvement in insomnia-related daytime impairments, involving not only the child but also the entire family, are expected. A better quality of sleep may ameliorate daytime behavior and even cognitive development and, for sure, might lead to an improvement of sleep-related psychological distress in the family.
The assessment should consider medical and psychiatric contributing factors, primary sleep disorders, and maladaptive behaviors related to sleep. The correct treatment should follow a specific pattern: a thorough sleep history/sleep diary prior to any intervention being planned, behavioral treatment strategies through the parents, circadian rhythm regulation, and pharmacological treatment.
The use of medications for pediatric insomnia should be diagnostically driven, and should be implemented in conjunction with empirically based behavioral treatment strategies and adequate sleep hygiene.
Future studies should address a number of shortcomings identified in our review. First, it is imperative to carry out new studies to identify objective and specific outcome indicators that can give measures of wake time after sleep onset, sleep onset latency, number of awakenings, sleep time, or sleep efficiency. The use of actigraphy should be an integrative part of studies in this field and also integrate information from multiple informants (e.g. parents, teachers, therapists, etc.). Second, a better understanding of the specific effects of the available treatments, in relation to specific clinical populations, is needed (e.g. RLS in children with ADHD or respiratory disturbances in Rett's syndrome). Third, well-designed, double-blind RCTs on large samples of children with NDDs comparing the different drugs against placebo should be carried out. Importantly, head-to-head and pragmatic trials would be important to understand how different drugs compare and rank in terms of effectiveness and tolerability.
Fourth, studies should be devoted to identifying the specific doses of all agents that may be required in younger children, and their potential for side effects and drug-drug interactions.
Fifth, an important step of future studies would be to analyze if drugs are able to improve cognitive functions in specific populations by improving sleep, also together with cognitive-behavioral therapy.
Finally, there is a need to investigate the long-term effectiveness of the different drugs by analyzing the possible tolerance and their eventual lack of efficacy over time (i.e. benzodiazepines).
Supporting information
Additional Supporting Information may be found in the online version of this article: Appendix S1. Search strategy and results from each database. • Benzodiazepines are not recommended in children and should only be used for transient insomnia; clonidine is used to improve sleep onset latency in ADHD subjects; trazodone and mirtazapine hold promise but require further studies.
• Orexin antagonists might be promising for children with NDDs as they act on a different neurotransmitter system with fewer interactions with other drugs commonly used in these children; however, no studies are available in children with NDDs.
• While no comprehensive evidence-based information is available to rank the available drugs in terms of efficacy and tolerability, we present our recommendations for the management of chronic insomnia in children with NDDs, based on available empirical evidence or expert consensus.
Areas for future research
• A standardized assessment of insomnia in children with NDDs should consider medical and psychiatric contributing factors, primary sleep disorders, and maladaptive behaviors related to sleep.
• Research on treatment of insomnia in this special population should focus on a multimodal and individualized approach: behavioral treatment strategies through the parents, circadian rhythm regulation, and pharmacological treatment. This will hopefully allow better health and quality of life of children and adolescents with NDDs and their families.
• Despite the widespread use of pharmacological treatment, the lack of well-designed, controlled studies concerning the efficacy, tolerability, dosage, and safety profile of hypnotic medications in children raise the need of further research.
• Well-controlled studies employing both objective polysomnography and subjective sleep measures are needed to determine the efficacy and safety of the currently prescribed pediatric sleep drugs.
• Mirtazapine, trazodone, and orexin antagonists are promising in the treatment of insomnia, but RCTs are needed to assess both the short-and long-term effects of these medications, as well as their efficacy in comorbid diseases that affect sleep architecture.
• Future, rigorous protocols are needed to guide clinical recommendations useful for clinical practitioners in their everyday practice.
